-February 7, 2023-BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN : FR0013421286 ALNEO), has been selected by a jury from the National Union of the Medical Technology Industry (SNITEM) in ordert o participate to the 8th edition of the start-ups day, organized on April 4th at la Cité des Sciences. This event brings together all start-ups […]

-December 12, 2022-BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN: FR0013421286 ALNEO), announces that they have been recognized and awarded in the category “diabetes devices” from the DCB Innovation Challenge 2022. Held every year, the DCB Open Innovation Challenge aims at fostering new initiatives and innovative projects in the domain of diabetes management.BOYDSense breath-based glucose monitoring […]

-September 12, 2019-Boston, Mass. – September 12, 2019 – The RESI Innovation Challenge showcased 38 emerging startups in the biotech, medtech, diagnostics and digital health fields.  All the competitors brought novel, exciting discoveries to the technology showcase […]